Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Conjugate or complex
Reexamination Certificate
1997-05-22
2001-10-23
Lankford, Jr., Leon B. (Department: 1651)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Conjugate or complex
C435S325000, C435S360000, C435S410000
Reexamination Certificate
active
06306398
ABSTRACT:
FIELD OF THE INVENTION
This invention relates to compositions of matter which are effective in inhibiting apoptotic cell death.
BACKGROUND OF THE INVENTION
Apoptosis is a normal physiologic process that leads to individual cell death. This process of programmed cell death is involved in a variety of normal and pathogenic biological events and can be induced by a number of unrelated stimuli. Changes in the biological regulation of apoptosis also occur during aging and are responsible for many of the conditions and diseases related to aging. Recent studies of apoptosis have implied that a common metabolic pathway leading to cell death may be initiated by a wide variety of signals, including hormones, serum growth factor deprivation, chemotherapeutic agents, ionizing radiation, and infection by human immunodeficiency virus (HIV). Wyllie (1980)
Nature
284:555-556; Kanter et al. (1984)
Biochem. Biophys. Res. Commun.
118:392-399; Duke and Cohen (1986)
Lymphokine Res.
5:289-299; Tomei et al. (1988)
Biochem. Biophys. Res. Commun.
155:324-331; and Kruman et al. (1991)
J. Cell. Physiol.
148:267-273; Ameisen and Capron (1991)
Immunol. Today
12:102-105; and Sheppard and Ascher (1992)
J. AIDS
5:143-147. Agents that affect the biological control of apoptosis thus have therapeutic utility in numerous clinical indications.
Apoptotic cell death is characterized by cellular shrinkage, chromatin condensation, cytoplasmic blebbing, increased membrane permeability and internucleosomal DNA cleavage. Gerschenson et al. (1992)
FASEB J.
6:2450-2455; and Cohen and Duke (1992)
Ann. Rev. Immunol.
10:267-293.
All references cited herein both supra and infra are hereby incorporated herein by reference.
A variety of food supplements containing, in part, partially processed plant extracts have been used to ameliorate the gastrointestinal disorders that often accompany chemotherapy, radiation and AIDS. The supplements generally contain carbohydrates, fat and plant protein hydrolysates. See, e.g., Tomei and Cope et al. in Apoptosis The Molecular Basis of Cell Death (1991) Cold Spring Harbor Laboratory Press.
Several proteinase inhibitors derived from plant extracts have anticarcinogenic activity. Troll et al. (1987)
Adv. Cancer Res.
49:265-283. The Bowman-Birk inhibitors are the best described of these inhibitors. Birk (1985)
Int. J. Pep. Pro. Res.
25:113-131. Bowman-Birk inhibitors are described as a family of disulfide bonded proteins with a molecular weight of about 8 kD which suppress cellular transformation. Chou et al. (1974)
Proc. Natl. Acad. Sci. USA
71:1748-1752; Yavelow et al. (1985)
Proc. Natl. Acad. Sci. USA
82:5395-5399; and Yavelow et al. (1983)
Cancer Res.
(
Suppl.
) 43:2454s-2459s. Crude soybean extracts containing Bowman-Birk inhibitors have been described. Kennedy et al. U.S. Pat. No. 4,793,996; PCT publication No. WO 94/20121; and Kennedy, A. R. (1994)
Cancer Res.
(Suppl) 54:1999s-2005s. Bowman-Birk inhibitors have also been described immunologically. WO 90/03574; and U.S. Pat. Nos. 4,959,310; and 5,053,327. Bowman-Birk inhibitors have also been found to have activity in degranulation of macrophages. Japanese Patent No. 63051335.
Lysophosphatidic acid (LPA) is found in a variety of plant products as are a variety of phospholipids. LPA as been found to have a variety of physiological activities including mitogenesis, growth factor and as an anti-wrinkle agent. U.S. Pat. Nos. 4,263,286; 4,746,652; 5,326,690; and 5,340,568. LPA is reviewed in detail by Moolenaar (1994)
TICB
4:213-219; and Eichholtz et al. (1990)
Biochem. J.
291:677-680.
SUMMARY OF THE INVENTION
The present invention encompasses methods of obtaining compositions that inhibit apoptosis and the compositions obtained thereby. The compositions are termed phytogenic apoptosis inhibitors (PAIs). The invention encompasses physiologically acceptable compositions suitable for administering the PAIs in an amount sufficient to modulate apoptosis. The invention further encompasses methods of use of the PAIs.
REFERENCES:
patent: 4263286 (1981-04-01), Nakajima et al.
patent: 4340586 (1982-07-01), Bekierkunst et al.
patent: 4695590 (1987-09-01), Lippman
patent: 4746652 (1988-05-01), Buckalew, Jr. et al.
patent: 4793996 (1988-12-01), Kennedy et al.
patent: 4818540 (1989-04-01), Chien et al.
patent: 4938961 (1990-07-01), Collins et al.
patent: 4959310 (1990-09-01), Brandon et al.
patent: 4959353 (1990-09-01), Brown et al.
patent: 5053327 (1991-10-01), Brandon et al.
patent: 5093505 (1992-03-01), Nishino et al.
patent: 5130298 (1992-07-01), Cini et al.
patent: 5140043 (1992-08-01), Darr et al.
patent: 5217717 (1993-06-01), Kennedy et al.
patent: 5238965 (1993-08-01), Piazza et al.
patent: 5326690 (1994-07-01), Xu et al.
patent: 5330972 (1994-07-01), Cope
patent: 5340568 (1994-08-01), Piazza et al.
patent: 5636187 (1997-06-01), Fujii et al.
patent: 0626177 (1994-11-01), None
patent: 63-51335 (1988-03-01), None
patent: WO 90/03574 (1990-04-01), None
patent: WO 94/20121 (1994-09-01), None
patent: WO 94/25621 (1994-11-01), None
Dialog® Abstract of JP Patent No. 63-51335 (Mar. 4, 1988). One page total.
Ameisen et al., “Cell dysfunction and depletion in AIDS: The programmed cell death hypothesis”Immunol. Today(1991) 12(4):102-105.
Billings et al., “The interaction of the potato-derived chymotrypsin inhibitor with C3H/10T1/2 cells”Carcinogenesis(1991) 12(4):653-657.
Birk et al., “A pure trypsin inhibitor from soya beans”Biochem. J.(1963) 87:281-284.
Birk, “The Bowman-Birk inhibitor”Int. J. Peptide Protein Res.(1985) 25:113-131.
Bligh et al., “A rapid method of total lipid extraction and purification”Can. J. Biochem. Physiol.(1959) 37(8):911-917.
Chang et al., “Effects of protease inhibitors on c-Myc expression in normal and transformed C3H 10T1/2 cell lines”Mol. Carcinogen.(1990) 3:226-232.
Chien et al., “A simple technique for multiorgan preservation”J. Thorac. Cardiovasc. Surg.(1988) 95:55-61.
Chien et al., “A simple technique for producing supravalvular aortic stenosis in animals”Cardiovascular Research(1988) 22(10):739-745.
Chien et al., “New autoperfusion preparation for long-term organ preservation”Circulation(1988) 78 (suppl. III):III-58-III-65.
Chien et al., “The effect of hibernation induction trigger on heart survival time during hypothermic storage”Hibernation Induction Trigger for Organ Preservation, C. Kerkaporta, ed., R.G. Landes Company, (1993) Chapter 6, pp. 106-115.
Chien et al., “Hibernation induction trigger for organ preservation”Medical Intelligence Unit(1993) R.G. Landes Co., Austin, Texas. A title page and table of contents are enclosed.
Chou et al., “Non-selective inhibition of transformed cell growth by a protease inhibitor”Proc. Natl. Acad. Sci. USA(1974) 71(5):1748-1752.
Christie,High-performance liquid chromatography and lipids, Oily Press Ltd., 1987, Dundee, Scotland. A title page and table of contents are enclosed.
Christie,Gas chromatography and lipids: a practical guide, Oily Press Ltd., 1989, Dundee, Scotland. A title page and table of contents are enclosed.
Cohen et al., “Apoptosis and programmed cell death in immunity”Annu. Rev. Immunol.(1992) 10:267-293.
Collins et al., “New organ preservation solutions”Kidney International(1992) 42:(suppl. 38):S-197-S-202.
Dawson et al., eds.,Data for Biochemical Research(1986) 3rd ed., Clarendon Press, Oxford. A title page and table of contents are enclosed.
Domínguez-Bello et al., “Cytotoxicity in MA-104 cells and rumen protozoa of some phytotoxins and their effect on fermentation by faunated and defaunated rumen inocula”J. Agric. Food Chem.(1993) 41:2045-2050.
Duke et al., “IL-2 addiction: Withdrawal of growth factor activates a suicide program in dependent T cells”Lymphokine Res.(1986) 5(4):289-299.
Eichholtz et al., “The bioactive phospholipid lysophosphatidic acid is released from activated platelets”Biochem. J.(1993) 291:677-680.
Funk et al., “Effect of fiber, protein source and time of feeding on methotrexate toxicity in rats”J. Nutr.(1991) 121:1673-1683.
Funk et al., “Effect of soy products on methotrexate toxicity in rats”J. Nutr.(1991)
Barr Philip J.
Bathurst Ian Cyril
Bradley John D.
Tomei L. David
Lankford , Jr. Leon B.
LXR Biotechnology Inc.
Sheridan & Ross P.C.
LandOfFree
Compositions which inhibit apoptosis, methods of purifying... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions which inhibit apoptosis, methods of purifying..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions which inhibit apoptosis, methods of purifying... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2592924